CELL STORY liquid microneedling: 50,000 Microspears, no needle gun

Let's get the tool in your hand before we talk about collagen. CELL STORY is liquid microneedling, and the needles aren't steel. They're siliceous spicules, grown as skeleton by a freshwater sponge, cleaned and size-selected, then painted onto a face in a liquid vehicle as a forest of about fifty thousand Microspears. Each one is needle-shaped silicon dioxide, typically a tenth to a quarter of a millimetre long and a few micrometres across. Human stratum corneum on the face is ten to twenty micrometres. Arithmetic says the spicule walks through the dead layer and into living epidermis. A steel stamp, by contrast, is a chosen millimetre depth, often 1.5 millimetres, which is seventy times the facial barrier and routinely meets capillary loops in the papillary dermis. Hence pin-point bleeding. Hence topical anaesthetic. Hence the injury look people associate with microneedling. The sponge needles aren't that object. They open transient channels through the stratum corneum, they carry the clinic's actives while those channels last, and they sit in the epidermis as a mild foreign body until the surface sheds them over about seventy-two hours. That's the physics. Hold those millimetres; they're why a painted forest looks nothing like a steel stamp.

In short. The facial paints tens of thousands of tiny glass needles from a sponge onto the face, rather than stamping steel through the skin.

Two jobs sit on that physics, and they run on different clocks — keep them in two pockets, because they really are two experiments. First, delivery. Papers on sponge spicules as transdermal devices show increased flux of macromolecules that intact skin would have stopped at the lipid mortar of the stratum corneum. The channels are real. They're also short-lived, on the order of hours, because lipids and keratinocytes close a hole the width of a few micrometres. Second, stimulus. The spicules themselves hang around until desquamation, about forty-eight to seventy-two hours, so the physical irritant outlasts the hole. Keratinocytes treat a forest of inert silica as a reason to talk to fibroblasts; fibroblasts treat that conversation as a reason to write collagen I and III over subsequent weeks. Percutaneous collagen induction, minus the gun, is Des Fernandes' name for the steel-needle parent of the same idea. Spicule microneedling is a shallower cousin. A two-hundred-micrometre silica needle doesn't remodel two millimetres of dermis, and we shouldn't ask it to. The version of a liquid facial that matches the millimetres is the barrier, the viable epidermis, and a milder fibroblast nudge. Depth first. Then the reading list.

In short. The glass needles open short-lived doors for the clinic's actives, then stay in the surface for a few days so repair cells keep working.

We stock lyophilised GHK-Cu and lyophilised KPV because those are the sequences the fibroblast-array and NF-κB papers actually dissolve into a well. Gly-His-Lys holding Cu²⁺ in a square-planar complex is Pickart's plasma tripeptide, a copper escort for lysyl oxidase and superoxide dismutase, a microarray claim about a repair transcriptome. Lys-Pro-Val is the C-terminal tripeptide of α-melanocyte-stimulating hormone, the fragment Luger and Haycock used when they wanted quieter NF-κB in keratinocytes without a tanning programme. Neighbourhood isn't identity. A copper tripeptide and a melanocortin tail share a tissue on a reading list and don't share a lock. Neither sequence is the product in the bowl at eLIVEate. JP's eight-step protocol puts amino acids, Centella and a calming complex into the channels the Microspears just opened. Those are the clinic's actives, a cosmetic protocol under a clinician's consent. The cakes on our listing are HPLC-characterised research solids. Different rooms, different paperwork, and we don't take a commission on the booking. The rest of this piece is the barrier physics you'd want before treating a facial and a vial as one object.

In short. The clinic paints its own actives into the channels. The named copper peptide and the named anti-inflammatory fragment live on a research shelf, not in that bowl.

Let's begin with a map rather than a recipe. This isn't a protocol for mixing a research vial into a facial, and it isn't an appointment written as physiology. Sponge spicules, stratum corneum, channel lifetime, Percutaneous Collagen Induction, the keratinocyte–fibroblast cascade, then the two ligands the skin literature actually names. Zhang, Kim and others on transdermal flux. Fernandes and Aust on needling histology. Pickart and Maquart on copper and collagen. Luger, Brzoska, Haycock on the α-MSH tail and IκB. Pollard and Borisy on the actin treadmill a crawling keratinocyte actually uses. Named papers, named numbers, named depths. A course of four at eLIVEate, typically a month apart, is how the clinic stacks a stimulus that histology will still see at week six. A single sitting can change how a complexion looks at seventy-two hours, which is when the spicules finish shedding. Those are different clocks, and they're both allowed to be true without anyone reconstituting a chromatogram into a yellow calming complex. Start with the millimetres. The ligands wait their turn.

In short. This page maps the glass needles, the skin wall they pierce and the nearby lab papers. It isn't a recipe for mixing a research vial into a facial.

Sponges build skeletons out of silica — glass, grown, not smelted. Demosponges and hexactinellids secrete siliceous spicules, amorphous hydrated silicon dioxide, around a proteinaceous axial filament of silicatein. Freshwater sponges of the Spongilla neighbourhood are the usual cosmetic source: stiff, high-aspect-ratio needles, cleaned of organic matter and size-selected so the population that reaches a Microspear vial is a tenth to a quarter of a millimetre long and a few micrometres across. That isn't a steel alloy. It's glass, in the honest mineral sense, SiO₂, brittle, chemically inert in the time a stratum corneum lives, sharp because a high aspect ratio concentrates force on a tiny tip. Human stratum corneum on the face is ten to twenty micrometres of dead, keratinised, lipid-mortared corneocytes. A two-hundred-micrometre needle doesn't negotiate that wall. It punches it. The arithmetic is the whole delivery argument, and it doesn't require a brand story. Spicules are old tools in marine biology before they were a facial. What CELL STORY did was put about fifty thousand of them into a liquid that a clinician can paint, rather than a stamp a clinician fires.

In short. Sponges grow glass needles as their skeleton. Cleaned and sorted, those needles punch through the dead outer skin but stay far shorter than a steel stamp.

Aspect ratio is the mechanical fact, and it's a lovely one. A few micrometres of diameter against one or two hundred micrometres of length is a needle, not a grit. Grit abrades. A needle concentrates load at a tip, parts a sheet, and leaves a conduit. Zhang, Mitragotri, Chen and colleagues, Molecular Pharmaceutics 2017, put marine-sponge spicules onto skin as a physical enhancer and measured increased flux of hydrophilic macromolecules that intact stratum corneum would have stopped. Kim and others, in the neighbouring sponge-spicule literature the clinic papers sit on, reported the same directional result: more transdermal movement once the silica forest is in. Those are device papers, Franz cells, tape-stripping, fluorescence in a section, the unglamorous measurements a delivery claim has to survive. They aren't a promise that a two-hundred-micrometre object remodels two millimetres of dermis. They're a promise that the brick wall has holes in it for a while. Hold that size. The next heading is the wall.

In short. A long, thin glass rod acts as a needle, not as sandpaper. Lab papers show it helps large molecules cross skin that would otherwise stop them.

About fifty thousand is a census of a painted forest, not a stamp pattern. A dermaroller or a motorised pen places needles on a grid: a few hundred penetrations per square centimetre if you're being kind, a few thousand if you stack passes, each one a chosen millimetre. A liquid vehicle carrying tens of thousands of spicules doesn't place them on a grid. It lays them down as a random, high-density field, some vertical enough to punch, some lying as irritant, some lost on a towel. The number is an order of magnitude for the face, not a counted lattice. That's why the channels are many and shallow rather than few and deep, and why bleeding is the exception rather than the design. A steel array that's honest about depth will tell you 0.5 millimetres or 1.5 millimetres and will have a reason for the anaesthetic. A Microspear protocol that's honest about depth will tell you one or two hundred micrometres and will have a reason there is no anaesthetic. Both can be serious. They aren't interchangeable tools wearing different adjectives.

In short. Tens of thousands of glass needles land as a dense scatter, not as a neat grid of deep holes. Many shallow punctures, not a few long ones.

Silicon dioxide in this setting is a material, not a mineral tonic. It doesn't dissolve into a silicic-acid story on the timescale of a weekend. It doesn't become a collagen cofactor. It doesn't occupy a receptor. It's an inert shard the epidermis has to lift out with the next few days of desquamation, and while it sits there it's a controlled foreign body: small enough not to be a splinter you can see, large enough that keratinocytes notice. Silica here isn't a mineral the dermis was craving — that's a needle confused with a nutrient. And the spicules don't vanish the moment the appointment ends: that's the channel confused with the shard. The channel is a hole in a lipid wall and it closes in hours. The shard is a piece of glass and it leaves when the surface sheds. Both facts are required. Neither is a cream.

In short. The glass doesn't melt into a vitamin. It sits as a tiny irritant until the outer skin flakes it away over a few days.

Call it a brick wall once, then drop the metaphor, because the architecture has names you can love. Corneocytes are the bricks: flattened, dead keratinocytes, packed with keratin filaments and a cornified envelope of involucrin, loricrin and small proline-rich proteins, cross-linked by transglutaminases. The mortar is a lipid lamella of ceramides, cholesterol and free fatty acids, secreted as lamellar bodies from the stratum granulosum and then organised into the sheets that actually stop water and stop most topicals. Peter Elias spent a career on those lipids. Madison's 2003 review is still the sentence a barrier paper has to live next to: the raison d'être of the epidermis is the barrier, and the barrier is this dead, lipid-sealed layer. On the face the whole stack is ten to twenty micrometres. On a palm or a sole it's thicker, which is why a facial protocol doesn't transfer to a foot by wish. Transepidermal water loss is the everyday readout that the mortar is intact. A cream that can't get past ceramides isn't a failed peptide. It's a cream sitting on a wall that was built to make it fail.

In short. The outer skin is dead flattened cells sealed with fats. That seal is the point of the epidermis, and most creams never get through it.

Macromolecules bounce off intact stratum corneum for a physical reason, not a moral one, which I find quietly satisfying. Molecular weight, charge, and a partition coefficient that hates both water and oil in the wrong ratio: the 500-dalton rule of thumb that cosmetic chemists still quote is a cartoon of a real filter. A three-hundred-dalton copper tripeptide is already near the edge of what intact barrier will admit in useful amounts. A fifteen-residue gastric fragment is over it. Hyaluronan of cosmetic molecular weight is a film, not a tourist. That's why the delivery half of microneedling exists as a field. Disrupt the mortar, even transiently, and the flux of things that previously sat on the surface rises. Tape-stripping does it by removing bricks. A solvent does it by disordering lipids, with the ethics that implies. A needle does it by making a hole. Sponge spicules are the hole method at epidermal scale. Zhang's 2017 macromolecule work is the measurement: hydrophilic cargo that intact skin stopped, moving once spicules were in. The clinic's actives, whatever their molecular weights, are being asked to use those holes for a few hours. After that the mortar rebuilds, as it's built to do.

In short. Large wet molecules mostly sit on intact outer skin. Punch tiny holes and they can briefly move in. The holes then close as the fat seal rebuilds.

Channel lifetime is hours, and that number is the one a delivery claim has to keep. A conduit a few micrometres across, through a lipid-sealed sheet, is a wound the size of a cell's patience. Surrounding lipids flow. Residual bodies from the granulosum keep arriving. Keratinocytes underneath are already a factory for a dead seal; they don't leave a pore open because a facial asked them to. Electrical resistance and transepidermal water loss after microneedling both move and then recover on a timescale of hours, which is the biophysical way of saying the wall is selfish. A steel channel at 1.5 millimetres is a different recovery, because you've also wounded dermis, and dermis doesn't close on a corneocyte clock. A spicule channel is an epidermal event. Delivery of the bowl's contents is therefore a same-day phenomenon, not a three-day infusion. People who write seventy-two hours of open doors have confused the shard with the hole. The shard is still there. The hole is not. What the shard is doing by then is stimulus, which is the next-but-one heading, and it isn't the same experiment as flux through a conduit.

In short. The holes themselves last hours, not days. After that the seal is back. Anything delivered through those holes has to travel on that short clock.

Desquamation is the other clock, and it's why the silica can still be in the surface on day two. Corneocytes are designed to shed. Kallikreins and other serine proteases, pH, and a water gradient from the granulosum outward decide how fast the outermost bricks let go. Forty-eight to seventy-two hours is a reasonable window for a facial stratum corneum to lift a population of micrometre-wide shards that were never going to migrate into fat. That's also why aftercare exists as a practical sentence: no harsh acids, no picking, sunscreen, because you've just asked a barrier to do two jobs at once — close the holes and then discard the tools that made them. Mild redness or tightness for a day or three is the clinic's expected downtime, which matches an epidermal foreign-body plus a barrier that's busy. Makeup and sun off for a day or two isn't mysticism. It's a wall under repair. A section of spicules sitting in epidermis is still talking to the surface until those bricks let go.

In short. The outer skin is always flaking. Over about three days it carries the glass needles out with it. The face can stay a bit tight while that happens.

A cream sits on ten to twenty micrometres of mortar. A two-hundred-micrometre silica needle walks through it. That sentence is the delivery argument, and it's millimetres, not a brand story. It's also the limit of the argument. Walking through stratum corneum isn't walking into reticular dermis. Viable epidermis on the face is another few tens of micrometres; the dermoepidermal junction, type IV collagen and laminin, sits under that; papillary dermis with its capillary loops sits deeper still. A Microspear that's 100–250 micrometres long, arriving at an angle, occupying some of its length above the surface, will spend most of its buried career in epidermis and, at most, the most superficial papillary hints. That's plenty for a channel. It isn't a 1.5 millimetre medical stamp. The liquid facial that matches its millimetres reaches the barrier and the living epidermis, and it nags the fibroblasts that live next door through cytokines rather than through a hole in their living room. Hold the depth. The next heading is the comparison: silica versus steel, millimetre versus millimetre.

In short. A cream sits on the dead seal. A glass needle this size walks through that seal into living outer skin, not into the deep, bleeding layer a steel stamp reaches.

A 1.5 millimetre steel needle is seventy times the thickness of facial stratum corneum, and long enough to meet the papillary vascular plexus. Capillary loops sit in dermal papillae, a few hundred micrometres below the surface depending on site, age and photodamage. When a stamp or a pen reaches them you get pin-point bleeding, which some protocols treat as a depth endpoint and some patients treat as the proof they bought an injury. Topical anaesthetic exists because that depth hurts. Orentreich subcision, Camirand needle dermabrasion, then Fernandes' named Percutaneous Collagen Induction: the steel literature is a dermal literature. You puncture, you don't ablate the epidermis the way a CO₂ laser does, you let a wound-healing cascade write collagen without a thermal eschar. Histology after medical needling shows more type I and type III weeks to months later, with the usual caveats of site, depth, pass count and who scored the sections. That's a real tool. It's also a different millimetre from a painted spicule, and collapsing them because both words contain needle is how a facial borrows a surgical paper.

In short. A one-and-a-half millimetre steel needle reaches blood vessels under the skin, which is why those treatments bleed and need numbing. The glass needles do not.

Papillary dermis isn't a mood. It's a place, with vessels. It's a vascularised, innervated connective tissue, type I and type III collagen in a looser weave than the reticular dermis below, fibroblasts, a lymphatic plexus, the first place a deep needle becomes a medical event. Epidermis has no vessels of its own; it lives on diffusion from those loops. A spicule that stays epidermal can inflame, can channel, can nag, and still spare the loop. That's why CELL STORY is usually described as no numbing, no blood. Not magic. Depth. Fitzpatrick phototype still belongs in the consult, because any epidermal insult can leave pigment behind in a darker epidermis, and post-inflammatory hyperpigmentation doesn't require a capillary to have been hit. Eyes, lids and neck are thinner and get the clinician's judgement rather than a copied pass count. None of this is mysterious. It's dosimetry on a surface that happens to be a face, and JP owns the settings. A research essay can name the millimetres. It can't set them.

In short. The living skin lining has no blood vessels of its own. Stay shallow and you usually skip bleeding. Pigment risk and thin sites still need a clinician's judgement.

We've sat with both tools, in different rooms, for different questions, and the millimetres are what decide which room you're in. A medical stamp is the tool you reach for when the question is a scar, a stretch mark, a dermal thickness you can see on ultrasound or on a biopsy, and the patient has consented to looking injured for a week. A spicule facial is the tool you reach for when the question is barrier, texture, a milder collagen nudge, and the patient has a diary that won't forgive a crust. eLIVEate books the second as CELL STORY, an hour, £240, or a course of four at £800, typically a month apart. Patriot Peptides doesn't take a cut of that diary. The neighbouring NEOGEN essay is thermal denaturation at sixty to seventy degrees, a bronze eschar, ninety days of rebuild, a different physics again. Dermalux is photons at cytochrome c oxidase and at bacterial porphyrins. Four procedures, four depths or four inputs, and the map essay files them so you don't have to guess. This page stays with the silica. Depth is the variable that decides whether you've a dermal paper or an epidermal one.

In short. Deep steel needling and this glass-needle facial are different depths for different questions. Heat plasma and LED light are different tools again.

Depth is the unglamorous variable, and it's the one that decides which paper you're allowed to quote. Liquid microneedling as a phrase wants the prestige of the steel literature and the downtime of a facial, which is a reasonable commercial wish and a poor histological one. Liebl and Kloth, among others, spent time reminding the field that microneedling is a cell-proliferation and collagen story only when you actually wound the cells that write collagen, or when you wound the epidermis hard enough that those cells hear it. A 200 micrometre insult can be heard. It isn't a 2 millimetre insult wearing a silk shirt. The honest sentence, the one we'll keep, is that CELL STORY does the two jobs a liquid facial can actually claim: it opens the wall for hours, and it leaves a foreign-body stimulus for days that fibroblasts downstream of keratinocyte cytokines treat as work. Collagen I and III can still rise over subsequent weeks. That rise won't be the rise of a medical stamp, and if the question is a scar at dermal depth, book the stamp. Physics first, then a booking if you want one.

In short. Calling it liquid microneedling borrows the fame of deep needling. The useful claim is a shallow punch and a few days of mild irritation that still asks collagen cells to work.

Des Fernandes, working in Cape Town in the early 2000s, named the steel-needle version Percutaneous Collagen Induction: puncture the dermis, spare the epidermis as a sheet, let a TGF-β3-leaning repair lay collagen without a thermal scar. The 2002 Aesthetic Surgery Journal note, the 2005 oral-and-maxillofacial review, then Aust, Fernandes, Kolokythas, Kaplan and Vogt in Plastic and Reconstructive Surgery 2008, with histology: more type I and type III, a thickened dermis, wrinkles and laxity as the clinical language those journals allow. The intellectual move was against ablation. A CO₂ laser removes epidermis and heats dermis; you buy a controlled burn and a controlled scar programme. Needling keeps the epidermal reservoir — hair follicles, sweat ducts, the same adnexal leftovers that let a peel heal — and asks the wound to stay in the puncture-and-rebuild register rather than the burn-and-contract register. TGF-β3 versus TGF-β1 is the ratio the scarless-foetal-skin literature made famous; Fernandes leaned on it. Whether every clinic stamp actually moves that ratio is a different, messier literature. The named idea is still the parent of every 'microneedling builds collagen' sentence in a waiting room.

In short. In the 2000s a surgeon named needle stamping as a way to build collagen without burning the surface off. Later histology showed more of the two main skin collagens.

The cascade, written without romance, is an inflammatory conversation that a dermis already knows how to have. Keratinocytes nicked or stressed release IL-1α, IL-1β, TNF, a set of alarmins. Platelets, if you've bled, dump TGF-β, PDGF, a clot's worth of instructions; if you've not bled, the keratinocyte set still reaches fibroblasts by diffusion across a basement membrane that's leakier in a wound. Fibroblasts answer with TGF-β of their own, with connective-tissue growth factor, with a burst of MMP-1 and MMP-3 to clear damaged fibrils, then with TIMP restraint and with new COL1A1 and COL1A3 transcription. HSP47, the collagen-specific chaperone in the endoplasmic reticulum, rises because you can't fold a triple helix without it. Lysyl oxidase, later, cross-links the secreted gel so it becomes a cable rather than a slip. Weeks, not hours. A 90-day neocollagenesis window is the number the plasma essay uses because thermal denaturation is a deeper, hotter insult. Spicule histology, where it exists, is a milder version of the same arc. You shouldn't expect the dermal band of a 2 millimetre pass from a 200 micrometre needle. You should expect a shallower, more proportional version of what a liquid facial can reach.

In short. Damaged lining cells call for help. Collagen-making cells answer by clearing old fibres — and writing new ones over weeks. A shallow glass insult is a quieter version of that call.

TGF-β isn't one instruction, and that's the bit worth slowing down for. TGF-β1 is the isoform a scarring wound leans on: more matrix, more myofibroblast, a contracture if you let it run. TGF-β2 keeps it company. TGF-β3 is the isoform the scarless and the needling literatures keep trying to enrich, a rebuild that doesn't become a keloid. Fernandes' PCI argument was that a puncture without ablation leans the ratio toward β3. That's a hypothesis with some histology behind it and a great deal of waiting-room copy in front of it. What a paper can actually show is more collagen I and III, a change in fibre organisation if the sections are good, and a clinical score if the trial was controlled, which many needling papers are not. Spicule work inherits the hypothesis at a shallower depth. It also inherits the waiting-room risk. We'll keep the named cascade — IL-1, TGF-β, keratinocyte–fibroblast crosstalk, collagen I/III — and won't pretend a painted forest has been scored against a 1.5 millimetre stamp in a randomised, blinded, biopsy-backed trial that the field is still waiting for. Adjacent biology. Not a head-to-head.

In short. One form of a repair signal builds scar; another rebuilds more quietly. Needling hopes for the quieter form. That hope isn't the same as a trial against a deep stamp.

JP's eight-step protocol is how those channels get used at eLIVEate, and it's the clinic's chemistry rather than ours. Amino acids, Centella asiatica, a yellow calming complex: those are the named families in the public description, a Korean sequence designed to occupy the hours the holes are open and the days the spicules still sit. Centella's madecassoside and asiaticoside literature is a wound-healing and fibroblast literature of its own, triterpenes, a different object from a lyophilised tripeptide. Amino acids in a bowl are nutrition for a keratinocyte in the most charitable reading and a vehicle in the honest one. The calming complex is what it sounds like, a post-insult anti-redness bet. None of those is Gly-His-Lys·Cu²⁺. None is Lys-Pro-Val. Pretending otherwise would be a good way to lose a partner we actually like, and it would be a category error a chromatogram wouldn't survive. The appointment is an hour. Results can show in seventy-two hours, which is the shed. A course of four, a month apart, is how they plan the collagen clock. Safe for most skins, including sensitive, is the clinic's claim to own in the consult, not ours to repeat as a certificate.

In short. The clinic's own eight-step mix goes into the holes: plant extracts, amino acids, a calming step. That mix isn't the named research peptides on a laboratory shelf.

Histology is the test a photograph can't sit. If a protocol claims collagen, the adult measurement is a biopsy, or at least a validated imaging proxy, at a stated week, with a control. Hydroxyproline, picrosirius, an antibody for type I versus type III, ultrasound thickness, a blinded wrinkle score: those are the tools. Most facial papers, spicule and steel alike, prefer photographs. Photographs are allowed as a clinic diary. They aren't a transcriptome and they aren't a millimetre. Fernandes' group did put sections on the page, which is why that 2008 paper is still the one to hand a sceptic. The spicule-as-device literature put flux on the page, which is why Zhang 2017 is the one to hand a different sceptic. Between them you've stimulus-as-histology in steel and delivery-as-flux in silica. CELL STORY, as an hour in Great Missenden, is a clinical protocol sitting on both neighbourhoods. It doesn't become a Fernandes biopsy by being painted, and it doesn't become a Franz-cell paper by being booked. Read both. Book the diary that owns the consent.

In short. Collagen claims want tissue sections or a serious scan at a stated week. Device papers measured holes and flow. A facial sits near both facts without becoming either paper.

Write the two clocks on the same line so they can't be swapped: hours for the hole, days for the glass, weeks for the collagen. Channel lifetime: hours. Spicule residence: about forty-eight to seventy-two hours. Collagen stimulus: weeks. Three numbers, three mechanisms, one facial. The hole is a defect in a lipid lamella and in a stack of corneocytes; it's closed by the same secretory and organisational programme that built the barrier in the first place. The shard is a piece of SiO₂ parked in that stack; it's removed by desquamation, the planned shedding of the outermost bricks. The stimulus is IL-1 and TGF-β and whatever else a keratinocyte writes when it's hosting a forest of glass; it's heard by fibroblasts that then transcribe collagen on a fibroblast clock. People who want the delivery to last three days are asking a wall not to be a wall. People who want the collagen on day one are asking a fibroblast not to be a fibroblast. The design is to use the hole while you've it and to leave the shard as a timed irritant.

In short. Holes close in hours. The glass stays about three days. New collagen, if it comes, takes weeks. Those are three different clocks in one treatment.

A foreign body in epidermis is a controlled irritant, not a granuloma seminar, and the distinction is millimetres. Micrometre silica, inert, in the dead and dying layers, is seen by living keratinocytes as damage-associated: ATP leak, IL-1α from pre-stored pools in the cornified neighbourhood, a NF-κB cassette the inflammation essays on this journal already named. Macrophages are less in the game than they would be in dermis, because you haven't, in the usual pass, parked glass next to a vessel. The point of leaving glass in the epidermis is exactly that lingering conversation. Pull the spicules out at the end of the hour and you have a short channel and a short nag. Leave them and you have two or three days of a mild, distributed, epidermal foreign-body that desquamation will finish. That's the opposite of a steel needle, which is in and out in a second and leaves a hole whose walls are living dermis. Different dwell, different depth, different cell set doing the talking. Collagen still happens, when it happens, because the talk reaches fibroblasts. It doesn't happen because silica is a collagen analogue. The mineral is the needle and the pebble. The protein is the cell's idea.

In short. Leaving the glass in the surface for a few days keeps lining cells mildly annoyed, so they keep signalling the collagen cells after you go home.

Seventy-two hours is also when the clinic says a result can show, which is a complexion clock rather than a collagen clock — and both can be true. Shedding a forest of spicules is a physical exfoliation. Tightness giving way, a bit of brightness, texture that photographs more kindly: those are surface events, corneocyte turnover plus whatever the eight-step left behind, plus oedema settling. Fine. Don't file them as type I fibrils in a 67-nanometre D-period. Fibrils are weeks, cross-links longer, organised dermis longer still. A course of four, a month apart, is how you stack a stimulus whose histology, if you were going to look, would still be moving at week six and week twelve. One sitting is allowed to be a glow without being a remodelling. NEOGEN uses three sittings because thermal denaturation is a 90-day rebuild; CELL STORY uses four because a milder epidermal nag is a different integral over time. Courses exist because transcription doesn't clock in for a single afternoon. Both clocks can be true at once: a surface glow at three days, and a collagen job measured in weeks.

In short. A brighter face at three days is mostly surface shedding. Thicker, better-organised collagen, if the treatment earns it, is a weeks-and-months job, which is why courses exist.

Aftercare is barrier arithmetic wearing a patient-information sheet, and it's more interesting than it sounds. You've opened the wall and left tools in it. Retinoids, acids, fragrance, and a week of unwise sun are how you turn a controlled insult into a pigment problem or a dermatitis. Sunscreen, bland emollient, hands off: the boring list. Makeup off for a day or two is the same list in a different font. Sensitive skin isn't a contraindication in the clinic's public language; it's a reason the consult exists. The spicule isn't a steroid and it isn't a patch test. A clinician who knows the face in the chair owns the yes. This page walks the clocks. If you take nothing else from the heading, take the refusal to let seventy-two hours mean open channels. Seventy-two hours means the glass is leaving. The channels were yesterday, which is the whole point of the heading.

In short. While the glass is coming out, treat the face as a wall under repair: gentle care, sun off, no picking. Three days is the glass leaving, not three days of open holes.

A keratinocyte is the barrier cell of epidermis and, when nicked, an inflammatory cell — one cell, two jobs. It stores IL-1α. It can write TNF, IL-6, IL-8, a chemokine cassette, antimicrobial peptides, a full NF-κB page. Haycock and Moustafa used that cell when they asked whether α-MSH fragments could stop p65 after TNF; the KPV heading will come back for that. For this heading the keratinocyte is the sensor of the silica forest. Mechanical stress, a breached envelope, a foreign tip in the viable layers: those inputs converge on the same transcription factors a cytokine would have used. The message has to cross the basement membrane to become a dermal event. Type IV collagen and laminin-332 are the sheet; in a wound they're disrupted enough for a cytokine to walk and, sometimes, for a cell to follow. Fibroblasts on the other side aren't waiting for a peptide from a catalogue. They're waiting for TGF-β, IL-1, PDGF if platelets were involved, and for the mechanical tone of a matrix that has just been irritated from above. That crosstalk is the repair half of Percutaneous Collagen Induction, and it doesn't require a millimetre of steel. It requires a keratinocyte that noticed.

In short. Lining cells sense the glass and send chemical alarms downward. Collagen cells in the layer below hear those alarms and start the rebuild.

A dermal fibroblast is a matrix factory, and I like picturing it that way. It transcribes collagen I and III as the bulk of the dermis, collagen IV as a basement-membrane component, decorin as the small leucine-rich proteoglycan that sets fibril diameter and sequesters TGF-β, SPARC as a matricellular contact protein. MMP-1 cuts native type I and III; MMP-3 chews proteoglycans and helps activate other MMPs; TIMPs hold those scissors. A fibroblast told to rebuild writes more collagen and more TIMP and, for a while, more MMP as well, because you can't lay a new cable in a mess without cutting the mess. Pickart and Margolina's GHK-Cu arrays claimed that factory can shift together under a copper tripeptide; that's a ligand story, next heading, not a spicule story. The spicule story is that the same factory can be told to work by a wound programme. Maquart already knew fibroblasts write more collagen when the instruction is right. Fernandes put the instruction in a needle. CELL STORY puts a shallower version of the instruction in a painted forest. The factory doesn't care which essay you're reading.

In short. The cells that build dermis write collagen, helpers that pack it and scissors that trim it. A wound signal, shallow or deep, is one way to switch that factory on.

Crawling is how a sheet actually closes, and crawling is actin — a treadmill, not a metaphor. G-actin is the monomer, 42 kilodaltons. F-actin is the filament. Barbed ends polymerise; pointed ends depolymerise; the treadmill is the protrusion. Pollard and Borisy, Cell 2003, is the document: assembly and disassembly as the motor of motility, not a metaphor. Keratinocytes at the edge of a micro-wound push a lamellipodium across the defect. Fibroblasts, if the basement membrane is asking them to, crawl on integrin contacts, focal adhesions, FAK and paxillin, the same machinery a tendon cell uses in a different essay. Thymosin β4 sequesters a reserve of G-actin so the cell has monomers for the next push; profilin hands them to barbed ends; Arp2/3 nucleates branches. Research TB-500 orbits the LKKTETQ actin-binding motif of that sequesterer. It's adjacent literature. It isn't in the bowl. The diagram that follows is here so a facial and an actin buffer don't collapse into one healing juice. A keratinocyte needs a treadmill to close a hole the width of a few micrometres. A peptide that buffers G-actin is a clerk of that treadmill. Silica isn't a clerk. Silica is the reason the hole exists.

In short. Skin cells close tiny wounds by building and taking apart actin filaments, a treadmill that pushes the cell forward. The glass made the hole. The cell's own skeleton closes it.

Weeks is the fibroblast clock, and that's why a course exists. COL1A1 transcription can move in a day in a dish; secreted, hydroxylated, packed, cross-linked collagen in a dermis is a different integral. Prolyl 4-hydroxylase wants iron, ascorbate and oxygen; scurvy is the existence proof that a helix without hydroxyproline is a failed cable. Lysyl oxidase wants copper and time. A 67-nanometre D-period, Hodge and Petruska's stagger, is an architecture, not a glow. Wunsch and Matuschka, in the LED essay, measured matrix changes after a course of red and near-infrared, not after a single afternoon; the same patience applies here. Book four sittings a month apart and you're stacking a stimulus while the last one is still being built. Book one sitting and you're allowed to like the seventy-two-hour surface. You aren't allowed to file it as a remodelled reticular dermis. Fibroblasts don't clock in for an afternoon. Neither do we, on this point.

In short. Switching on collagen genes is faster than building a finished, cross-linked cable in real skin. That slower job is why the clinic books a course, not a single visit.

MMP and TIMP are the scissors and the sheaths, and a wound programme moves both. Early, you want MMP-1 to cut damaged type I so the site isn't a mess of denatured fibrils. Later you want TIMP-1 and TIMP-2 to stop that cut becoming a hole. Photoaged dermis is already loud in MMP-1, which is Campisi's SASP neighbourhood as well as a sun neighbourhood; a ligand or a procedure that quiets MMP and raises TIMP is sitting next to ageing whether anyone names it or not. GHK-Cu arrays put TIMP up and MMP-1 and MMP-3 down, which is why that tripeptide is on this reading list. A spicule insult will, like any wound, raise MMPs first. Resolution is the interesting half. A facial that only ever inflamed would be a bad facial. A facial that inflames and then resolves, with fibroblasts laying I and III and TIMPs catching the scissors, is the arc Fernandes wanted from steel and that a shallower cousin can still attempt. Measure, if you're in a lab, MMP-1, TIMP-1, hydroxyproline, and a week. A photograph of a cheek isn't those four.

In short. Wound repair first cuts damaged collagen, and then holds the cutters in check. The useful ending is new, ordered collagen, not endless inflammation.

If you've just made thousands of micro-channels, and fibroblasts are about to write collagen, the reading list starts with copper. Loren Pickart, fractionating human plasma in the early 1970s, found a tripeptide that made old liver tissue in culture synthesise protein like young tissue. Glycine, histidine, lysine. It usually arrived with a copper ion attached, which turned out not to be a contaminant. Pickart and Thaler, 1973. Plasma GHK, on his numbers, sat near 200 nanograms per millilitre at age twenty and about 80 nanograms per millilitre at age sixty. Three residues is small enough to be underestimated and chemically tidy enough to survive scepticism. Histidine's imidazole is the classic copper ligand. Backbone nitrogens complete a square-planar Cu²⁺ complex, mass about 340.7 daltons, CAS 89030-95-5. Lysyl oxidase needs that metal to turn lysine in collagen and elastin into the aldehydes that cross-link. SOD1 needs it at the active site to disproportionate superoxide. Free Cu²⁺ is a Fenton reagent. The complex exists to deliver the metal without a radical mill in the medium. That's already enough to be on a facial's reading list. It isn't enough to be in the bowl.

In short. A three-amino-acid piece of blood holds copper so collagen-finishing enzymes can use the metal without it leaking as a damaging ion.

Maquart, Pickart, Borel and colleagues, FEBS Letters 1988, put the copper complex on cultured fibroblasts and measured more collagen — still the paper I'd put in your hand first. That paper is still the one to hand a sceptic who thinks this ligand is a moisturiser. The readout was collagen. The cells were fibroblasts. The ligand was GHK-Cu. Wegrowski, Maquart and Borel followed with sulphated glycosaminoglycans, the proteoglycan half of the same neighbourhood. Those are protein and carbohydrate outputs, not a four-thousand-gene spreadsheet, and they don't require you to believe anything extraordinary about transcription. A fibroblast given copper in a form it can use, in a medium that may have been marginally copper-limited, will finish more matrix. Decorin, SPARC, the factory named above, sit on the same street. β-Aminopropionitrile, the sweet-pea toxin, inhibits lysyl oxidase and leaves tissue fragile; that's the existence proof, older than GHK, that the cross-link isn't a cosmetic detail. A copper-delivery reagent sits on the other side of the same enzyme. Assays that ignore copper aren't studying this molecule. Assays that dump the molecule into a facial and skip the chromatogram aren't studying this molecule either.

In short. In 1988 the copper complex made cultured collagen cells produce more collagen. That finding needs the metal — and a named chain, not a cream caption.

The later microarray work — Pickart, Vasquez-Soltero, Margolina — reported thousands of human transcripts shifting in cultured cells treated with the complex: collagen I, III and IV up, decorin up, SOD up, some MMPs and a fibrinogen and metastatic cassette down. Breadth is the extraordinary claim. 2000s arrays were noisy. Multiple-testing correction wasn't always the religion it's now. RNA-seq replication is the live question, and the copper essay on this journal treats it as a live question rather than a finished map. Copper delivery to LOX and SOD is enough to be interesting even if the spreadsheet shrinks. The point for a CELL STORY page is narrower. A transcriptome is a claim about a defined ligand in a defined cell. A yellow calming complex in an eight-step protocol is a clinic recipe. You can believe both. You can't merge them by writing copper peptides on a blackboard and pointing at Great Missenden. The lyophilised cake we list is Gly-His-Lys·Cu²⁺, HPLC-characterised, a mass, a certificate. Topical cosmetic peptides in a facial are a different regulatory object. We're happy to keep the two objects named, because they really are two objects.

In short. Gene-chip papers claimed the copper tripeptide shifts a huge set of repair genes. That's a lab claim about one named chain, not a description of the facial mix.

Lysyl oxidase finishes the gel, and that sentence is why a copper chaperone and a collagen-induction facial share a shelf without sharing a stopper. Secreted type I is a hydrogen-bonded rope until LOX oxidatively deaminates specific lysines and hydroxylysines to aldehydes that then condense. No copper, no lysine tyrosylquinone cofactor, no aldehyde, no cable. A culture deprived of copper makes a weak gel. A dermis asked to rebuild after micro-injury will need that enzyme whether or not anyone reconstituted a tripeptide. Dietary copper, ceruloplasmin, ATP7A loading in the trans-Golgi: the body already has a logistics network. GHK is a small circulating complex that sits on the same chemical problem at peptide scale. Putting the vial into the channels isn't a protocol we'll write. Putting the paper next to the facial is a reading list. Adults can want both information and a treatment without anyone bundling them. We'll keep the vial and the bowl in different rooms. Hold the metal until then.

In short. New collagen has to be stitched together by a copper enzyme. The named tripeptide is one way labs deliver that metal. It isn't a step in the clinic protocol.

The second ligand the skin literature actually names is smaller than a tan, which I still find slightly delightful. KPV is lysine-proline-valine, mass 342.4 daltons, CAS 67724-34-9, the last three residues of α-melanocyte-stimulating hormone. α-MSH is thirteen residues, Ac-SYSMEHFRWGKPV-NH2, a POMC product, a pigment hormone that also calms inflammatory transcription. The tanning pharmacophore sits in the middle, His-Phe-Arg-Trp, the tetrapeptide melanocortin receptors actually want in the pocket. Keep the tail. Lose most of the pigment, most of the MC4R appetite agonism, most of the autonomic extras a cyclic analogue brings into a first-in-human room. What remains is stubborn enough, in the papers that bother to measure it, to suppress NF-κB in keratinocytes and macrophages, with evidence it can ride the intestinal peptide transporter PepT1. Luger, Brzoska, Böhm, Haycock, Moustafa, Getting: those are the papers. Put it with inflammatory tone in a barrier tissue. Put pigment with a different ligand. A spicule facial is, among other things, a few days of controlled epidermal irritation. Quieting NF-κB is the neighbouring question, not the appointment.

In short. The last three amino acids of the tanning hormone keep much of the calming effect on inflammatory genes and almost none of the pigment.

Nuclear factor kappa-B is a transcription-factor family, not a mood, and the cassette it writes has names. In the canonical pathway p65/RelA sits in the cytosol bound to IκBα. IKK phosphorylates IκBα on serines 32 and 36; the inhibitor is ubiquitinated and destroyed; p65 goes to the nucleus and writes TNF, IL-6, IL-1β, IL-8, COX-2, a cassette of adhesion molecules. A keratinocyte hosting silica will run some of that page. A keratinocyte hit with TNF will run more of it. Luger's group and Haycock's group showed that α-MSH, and then KPV, can preserve IκB after TNF, so p65 stays out, so the cassette stays quieter. Residual activity when MC1R is missing or blocked is the intellectual reason to reach for the fragment instead of Melanotan II when a tan would confound the assay. Cyclic AMP and PKA are the default melanocortin second messengers; in some of these assays they still matter, and in others the tail quieted NF-κB without a cAMP rise you could measure. The fragment isn't a weaker key for the same lock. It's a short chain that can still leave a cytosolic inhibitor standing after the pigment lock has been taken off the door.

In short. Inflammatory genes switch on when a holding protein is destroyed and the switch enters the nucleus. The three-letter fragment can help keep that holding protein in place.

PepT1, SLC15A1, is a proton-coupled oligopeptide transporter whose native cargo is dietary di- and tripeptides. Dalmasso, Merlin and colleagues made KPV's ride on that transporter the sentence a gut paper has to cite: oral fragment, DSS colitis, the benefit lost in a PepT1-null. Skin isn't gut. Keratinocytes aren't enterocytes. A facial isn't a drinking-water study. The transporter sentence belongs here anyway, because it's why the fragment exists as a pharmacokinetic object distinct from α-MSH, and because people who file KPV under skin have a habit of borrowing the gut paper without borrowing the door. On skin the interesting door is still being argued: residual MC1R, a different receptor, uptake that isn't PepT1. Haycock's keratinocyte p65 work doesn't require you to solve that door before you can find the paper interesting. It does require you not to write the catalogue vial as a moisturiser and not to write the moisturiser as Lys-Pro-Val. Three residues, a named transcription factor, a clinic irritant that will run NF-κB for a few days. Adjacent. Not mixed.

In short. In the gut this fragment can enter on a food-peptide transporter. Skin lining is a different door. The useful skin fact is quieter inflammatory genes, not a borrowed bowel study.

Melanotan II occupies MC1, MC3, MC4 and MC5 on purpose: pigment, appetite, flushing — a pan-agonist Hadley built to occupy the sheet. Setmelanotide occupies MC4R as a licensed medicine in rare genetic obesity. Afamelanotide is [Nle4, D-Phe7]-α-MSH, the linear photoprotective analogue. KPV is the design move in the other direction. If pigment is the question after a facial, that's a different receptor, MC1R, and a different essay. If inflammatory tone in a barrier is the question, the tail is the ligand the papers actually weighed. BPC-157's endothelial and nitric-oxide papers are a third, more gastric, stretch of the same shelf, a fifteen-residue proline-rich fragment that forums keep bundling with everything that ever healed in a rodent. None of those sequences is the product in the bowl. They're the defined ligands a laboratory uses when the question is collagen, inflammatory tone, or repair. We weigh them. JP paints Microspears. Different rooms.

In short. Tanning analogues turn many pigment and appetite receptors on at once. This fragment was kept because it does not. A stomach repair chain is a third, separate object again.

Say it in one paragraph so it doesn't have to become a refrain: two rooms, two objects. CELL STORY at eLIVEate Me in Great Missenden is a clinician-owned protocol: about fifty thousand siliceous Microspears, an eight-step sequence of clinic actives, an hour, a course of four if that's how the diary is planned, consent, aftercare, a partner clinic we don't take a commission on. Lyophilised GHK-Cu and lyophilised KPV in our catalogue are research sequences, HPLC-characterised, labelled for laboratory use, a mass, a certificate, a reconstitution kit. Topical cosmetic peptides in a facial are a different regulatory object from those solids. Same tissue on a reading list. Different legal class, different sterility file, different job. Mixing them in a bowl isn't a protocol. We don't invent those, and we don't take a commission on the booking either. Partner clinic. Their diary, their consent, their painted forest. Adults can want both a paper and an appointment. Bundling them is how a research reagent becomes a medical claim it isn't allowed to be, and how a clinic becomes a webshop it's not. The physiology above doesn't depend on that split. The label does.

In short. The facial is a clinic treatment with its own mix. The freeze-dried copper peptide and the freeze-dried three-letter fragment are laboratory chemicals. Related topic, different law.

Cosmetic peptide-class ingredients are allowed to be interesting and still not be a chromatogram of one chain. A serum can contain a copper peptide at a declared percentage, or a hydrolysate plus a copper salt plus a sentence that borrowed Pickart without borrowing his peak. It can contain a palmitoyl oligopeptide, a matrikine, a fragment of collagen that's still a population. Identity on a research vial is a one-letter code, a calculated mass, a main HPLC peak at 214 nanometres, a matching mass spectrum. Identity in a bowl is a proprietary formula a clinician trusts. Both can be serious. They fail different tests. Asking a yellow calming complex to show a single mass is a category error. Asking Gly-His-Lys·Cu²⁺ to be the unnamed peptide in a Korean step is the same error in the other direction. GLOW, on our shelf, is 50 milligrams of GHK-Cu plus 10 milligrams each of BPC-157, TB-500 and KPV, an 80 milligram cake so a bench that wants four named sequences doesn't open four caps. That's a logistics decision. It isn't a facial. It isn't JP's protocol. Cap-count isn't a course of four.

In short. A clinic cream may contain peptide-like ingredients as a mixture. A research vial is one named chain with a measured mass. A four-chain lab cake is still not a facial.

eLIVEate is a separate company — a medical-aesthetic clinic in Buckinghamshire, JP's rooms, a Wix diary, CE-marked devices and cosmetic protocols that clinic law already knows how to hold. Patriot Peptides is a research-reagent catalogue. The partnership is a reading list and a postcode-adjacent curiosity, not a bundle SKU and not a revenue share on the booking. NEOGEN, Dermalux, in-clinic NAD+ and CELL STORY are four procedures on their side. GHK-Cu, KPV, BPC-157, TB-500, β-NAD+ are characterised solids on ours. The map essay is the index so you don't have to guess which paper sits next to which appointment. This page is the silica, the wall, the clocks, and the two ligands people keep trying to pour into the forest. £240 for an hour, £800 for four, no numbing, no blood, downtime a day or three of tightness: those are their numbers. ≥98 percent HPLC, a mass, a reconstitution kit: those are ours. Write both in the same journal without collapsing them and you have a desk. Collapse them and you've a category error neither room asked for.

In short. The Buckinghamshire clinic and the research catalogue share curiosity and a map of papers. They don't share a product, a booking fee, or a mixing protocol.

BPC-157 is GEPPPGKPADDAGLV, a proline-rich fifteen-residue fragment of a gastric-juice protein, with VEGFR2 and nitric-oxide papers, endothelium, a rat-heavy bibliography. TB-500 orbits LKKTETQ, the actin-binding motif of thymosin β4, a G-actin buffer, a crawl assay if you actually run G-actin binding. Forums glued those two to GHK-Cu and KPV because all of them showed up in injury models and all of them were short enough to lyophilise. Biochemistry did not glue them. One talks to a receptor tyrosine kinase. One parks actin monomers. One holds copper. One preserves IκB. There is no shared receptor across that sentence. There is a shared customer: a laboratory that reads barrier and repair papers. Customer isn't mechanism. The actin-treadmill diagram was the crawl. The copper diagram was the metal. The melanocortin map was the tail. This map is the refusal to let four ligands and a facial become a smoothie. If a peptide is in an appointment, it will be in the clinician's protocol. If it's in this journal, it's a defined sequence with a paper next to it. Read the map and then book, or don't.

In short. Four short lab chains keep being filed with this facial because all of them appear in repair stories. They occupy four different jobs. The facial is a fifth object.

Start with the physics — the millimetres, the clocks, the forest. About fifty thousand siliceous Microspears, freshwater sponge, SiO₂, 100–250 micrometres, painted, not stamped. Stratum corneum on the face is 10–20 micrometres, so the needle walks through the dead layer into living epidermis and usually spares the papillary loops that make a 1.5 millimetre stamp bleed. Channels last hours; lipids and keratinocytes close a micrometre hole. Spicules shed with the surface over about seventy-two hours; that lingering foreign body is the stimulus. Keratinocytes write IL-1 and a TGF-β conversation; fibroblasts lay collagen I and III over weeks. Fernandes named the steel parent Percutaneous Collagen Induction; Aust put histology on it; a painted forest is a shallower cousin, not a 2 millimetre pass in a silk shirt. Zhang put macromolecule flux on the silica side. Then, if a ligand's paper is actually about that physics, read the ligand. GHK-Cu for copper, LOX, a fibroblast factory. KPV for IκB, a quieter NF-κB, inflammatory tone without a tan. A facial isn't a stack, and we won't write you one.

In short. Start with how long the glass is, how thick the skin wall is, and how long the holes and the glass last. Then open the nearby peptide papers.

The public papers are the reading list, and they're short enough to actually read on a couple of evenings. Zhang, Mitragotri, Chen, Molecular Pharmaceutics 2017, sponge spicules as a macromolecule enhancer. Fernandes 2002 and Aust, Fernandes, Plastic and Reconstructive Surgery 2008, Percutaneous Collagen Induction, histology included. Elias on epidermal lipids; Madison 2003 on why the epidermis exists. Pollard and Borisy, Cell 2003, so the treadmill stays a motor and not a metaphor. Pickart and Thaler 1973, Maquart 1988, the copper isolation and the collagen dish. Brzoska, Luger, Endocrine Reviews 2008, and Haycock on p65 in keratinocytes, so the tail stays an NF-κB fragment. Dalmasso 2008 if you need to know why PepT1 made the gut papers coherent and why a face is still not a colon. The GHK-Cu essay and the KPV essay on this journal for the ligands at catalogue length. The map essay for the four procedures. That's a fortnight of evenings, not a personality. The captions that treat a painted forest as a 2 millimetre stamp, or a chromatogram as a yellow complex, will still be there when you come back, and they will look smaller.

In short. Named papers cover the glass needles, needle-built collagen, the skin wall, copper-collagen chemistry and the anti-inflammatory tail. Read those before a caption.

Leave with a map of the biology, not a basket of products. CELL STORY is silica spicules, a forest of about fifty thousand, channels for hours, shards for three days, collagen on a fibroblast clock. It's booked in Great Missenden, an hour, a course of four if that's the plan, JP's eight-step in the channels. GHK-Cu is three residues and a metal, a square-planar delivery to lysyl oxidase, a microarray claim still awaiting a modern RNA-seq. KPV is three residues and an IκB story, a melanocortin tail that doesn't owe you a tan. BPC-157 and TB-500 are other clocks. Steel PCI is a deeper parent. Nitrogen plasma is heat. LED is cytochrome c oxidase. Intact NAD+ is a cofactor, in clinic a different product again. The painted forest doesn't inherit those pharmacokinetics, those receptors, or those certificates. If your question is the facial, book the clinician who owns the device and the bowl. If your question is the ligand, the cakes are on the listing, with a chromatogram, for the assay that topology demands. If your question is a bundle, we don't sell one.

In short. Carry this: glass needles, short-lived holes, a few days of shards, weeks of collagen talk, and two named lab chains that rhyme with that biology without being in the bowl.

This page won't dose you. It won't tell you how to paint a face, how many spicules make a protocol, how to combine a copper tripeptide or a melanocortin tail with an eight-step Korean sequence, or what a person should expect from a Fernandes biopsy they don't have. It won't launder a Franz-cell flux into a booking, or a waiting-room photograph into type I architecture. The papers that already ran the models wrote their methods: millimetres of steel, micrometres of silica, nanomolar ligand in a dish, a week of hydroxyproline. Go there if you're running an experiment. Stay here if you wanted the forest distinguished from the stamp, the hole distinguished from the shard, and the bowl distinguished from the cake. Dosing a research solid into a channel, stacking four ligands because a forum said glow, and filing a painted sponge skeleton as a medical-needling equivalent are category errors we won't make. The stratum corneum will still be ten to twenty micrometres in the morning, and a two-hundred-micrometre needle will still walk through it, whether or not anyone opened a vial.

In short. This is the biology of the glass needles and the nearby papers, not instructions for using either. The clinic owns the facial. The lab papers already contain their methods.

Research-use-only. Not for human consumption / not a medicine. The lyophilised GHK-Cu and KPV on the listing are laboratory reagents, HPLC-characterised at ≥98 percent, labelled for in-vitro work: a fibroblast collagen dish, a LOX activity assay, a keratinocyte p65 blot, an IκB Western, a copper-matched control, a PepT1 competition if the tissue you actually have is gut. The physiology in the paragraphs above is public, cited, and older than the vials. Use it to design the experiment you have the controls for, with the depth named, the clock named, and the ligand named only if the paper is about that ligand. Read Fernandes, read Zhang, read Pickart, read Luger, then weigh the cake or book the diary. We will sell you the sequences. We won't tell you they're a facial, and we won't tell you a facial is a chromatogram. Barrier physics is a set of millimetres. Collagen is a set of rates. Both you can measure, in a section or in a well, with the objects kept in the rooms they belong to.

In short. Those named chains are research chemicals for experiments, not a facial and not a medicine. The glass-needle treatment is booked with the clinic that owns it.